PubMed دسترسی آزاد

Artificial Intelligence in Pharmaceutical Care: Transforming Drug Discovery, Development, and Patient-care Delivery.

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

The integration of artificial intelligence (AI) into pharmaceutical care represents a paradigm shift in healthcare delivery, offering unprecedented opportunities to revolutionize medication management, accelerate drug development, and enhance patient outcomes. This comprehensive review synthesized evidence from global literature (2021-2025) examining AI applications across drug discovery and development, clinical trials optimization, medication therapy management, and pharmacy operations. The AI demonstrated prediction accuracies of 86-98% in drug discovery, 80% improvement in clinical trial recruitment efficiency, and 32.7% increase in medication adherence over standard care. The global AI drug discovery market, valued at $1.5 billion (2023), is projected to reach $11.8 billion by 2030, reflecting substantial industry investment. However, implementation challenges persist including data quality concerns (30% accuracy in some datasets), regulatory compliance issues, and algorithmic bias (8-12% performance variations across demographics). Successful implementation requires coordinated efforts across technological development, regulatory frameworks, healthcare professional training, and continuous validation protocols addressing technical, organizational, and ethical dimensions simultaneously.

متن کامل اصلی

نسخه دارای مجوز در منبع علمی در دسترس است.

لینک مستقیم از metadata منبع گرفته شده و در تب جدید باز می‌شود.

باز کردن متن کامل

کلیدواژه‌ها

Artificial intelligenceDrug discoveryMachine learningMedication managementPersonalized medicinePharmaceutical care
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

Flibanserin safety in real-world use: a decade of US Food and Drug Administration Adverse Event Reporting System pharmacovigilance evidence.

BACKGROUND: Flibanserin, a centrally acting 5-HT1A agonist and 5-HT2A antagonist, is the first approved therapy for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Despite its clinical availability, post-marketing data on real-world safety remain limited. METHODS: A retrospective pharmacovigilance analysis was conducted using the US Food and Drug Administration Adverse Event Reporting System from 2016 to…

PubMed2026

A Retrospective Evaluation of a Pharmacist-Driven Urgent Care Microbiology Review Program.

BACKGROUND: Pharmacist-driven microbiology review programs have been thoroughly described in the emergency department setting. However, there is limited evidence for programs in outpatient settings, especially for urgent care settings. The purpose of this study is to evaluate a pharmacist-driven urgent care microbiology review program to determine the impact of its implementation. METHODS: This retrospective cohort study evaluated urge…

PubMed2026

Key Performance Indicators for Clinical Pharmacy Practice and Administration in Inpatient/Acute Care Settings: An Opinion of the Clinical Administration Practice and Research Network of the American College of Clinical Pharmacy.

Key performance indicators (KPIs) are quantifiable measures that describe critical success factors of an organization. Their vital role in ensuring the delivery of quality health care services necessitates the development of KPIs relevant to inpatient clinical pharmacy practice. This opinion paper from the American College of Clinical Pharmacy (ACCP) Clinical Administration Practice and Research Network (CADM PRN) describes the rationa…